Uniting our global researchers for melanoma
28 October 2016
Melanoma Institute Australia (MIA) is bringing to Sydney some of the world’s leading melanoma researchers and clinicians today for the Australasian Melanoma Conference.
More than 380 researchers, clinicians, nurses and students are attending the two-day conference held at the Sofitel Wentworth in Sydney. The conference, hosted by MIA, is bringing together some of the greatest minds in melanoma research to showcase current practice and research innovation that will make a difference to the lives of melanoma patients.
MIA’s Associate Professor Robyn Saw, Chair of the Australasian Melanoma Conference, says this year’s event is an opportunity for physicians and researchers to learn about ground-breaking research and revolutionary melanoma treatment.
“The conference is a truly unique opportunity to build strong Australasian collaboration and to acquire information and knowledge to use in every day practice,” Associate Professor Saw says.
During the conference, MIA’s Associate Professor Jonathan Stretch AM is launching the new eBook Melanoma Principles & Practice, an interactive multi-touch e-textbook on melanoma care and treatment aimed at specialists.
Written and designed by MIA, the eBook is set to become an ultimate resource on melanoma, delivering specialists a seamless experience that supplements the text with interactive visual supports to build a multi-dimensional level of understanding that would not be possible from a printed book.
The Conference features a number of international keynote speakers. Dr Vernon Sondak from the Moffitt Cancer Center in the US is discussing melanoma in children and how to improve diagnosis and management, as well as communication with the young patient and their family.
Associate Professor Jennifer Wargo from MD Anderson Cancer Center is discussing her research on how gut flora – known as the microbiome – play a role in determining how well a patient responds to treatment.
“There is emerging evidence regarding the role of the microbiome in response to melanoma therapy, and it is quite likely that we will modify the microbiome to enhance responses to therapy in the upcoming months and years,” says Associate Professor Wargo.
Professor John Thompson AO from MIA is reporting on the new electronic clinical practice guidelines for the diagnosis and management of melanoma.
“Things are moving quickly in melanoma management. A comprehensive systematic review of the evidence was timely," Professor Thompson says. “Extensive use of the new guidelines will help to ensure that clinicians have access to the latest evidence-based recommendations when diagnosing and caring for people with melanoma."
More than 30 speakers are presenting at the Australasian Melanoma Conference, including a contingent of MIA experts such as Professor Richard Scolyer and Professor Georgina Long, as well as other eminent Australians in the field such as Professor Grant McArthur and Dr Mark Shackleton from the Peter MacCallum Cancer Centre.
Delegates are sharing insights and key learnings on social media throughout the day using the hashtag #MelanomaConf2016.
The Australasian Melanoma Conference is proudly sponsored by Bristol-Myers Squibb, MSD, Novartis, Sonic Healthcare, Amgen, Laverty Pathology and Pierre Fabre Australia.
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
“I had a complete response within about six months. All of my tumours disappeared."
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.
Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.